Travere Therapeutics, Inc. announced that its chief medical officer, Noah Rosenberg, M.D., would be transitioning to an executive advisor role effective January 1, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.17 USD | -0.97% |
|
+0.56% | -20.24% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.24% | 546M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- TVTX Stock
- News Travere Therapeutics, Inc.
- Travere Therapeutics, Inc. Announces Executive Changes